- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- Selected as a pilot for the Whole Lifecycle Assessment (WLA) approach.
- Process:
- MTA Standard
- ID number:
- 6689
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Related links
- Consultation on draft scope and guideline update
- Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 January 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 13 January 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: please see section 4 of the draft guidance consultation of the Osteoporosis: risk assessment, treatment, and fragility fracture prevention update. |
For further information on our processes and methods, please see our CHTE processes and methods manual